Navigation Links
GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
Date:12/6/2008

leeding.(1) Approximately 60,000 individuals in the U.S. have the disorder.(2)

"Patients with chronic ITP often have a difficult time managing their disease. They may experience excessive bruising, bleeding and sometimes more serious hemorrhages that can rarely be fatal. Until recently, ITP patients have had few options well demonstrated to be effective in the long term," said James Bussel, M.D., director of the Platelet Disorders Center, Children's Cancer and Blood Foundation Division of New York Presbyterian/Weill Cornell Medical Center. "As the RAISE study demonstrates, PROMACTA is an important new oral treatment option for ITP patients that is effective in maintaining a hemostatic platelet response."

The RAISE Study (Abstract #400 Presented on December 8, 2008 at 11:45 a.m.)

RAISE, a global, six-month, double-blind, placebo-controlled, Phase III study was designed to evaluate the safety and efficacy of PROMACTA in previously treated adults with chronic ITP and with platelet counts less than 30,000/microliters. The study enrolled 197 patients (PROMACTA: n=135; placebo: n=62) and, of these, approximately 50 percent had platelet counts less than or equal to 15,000/microliters; about 50 percent were receiving simultaneous ITP therapies at randomization; around 35 percent were splenectomized, and more than 50 percent had received at least three prior ITP medications. Patients began once daily treatment with PROMACTA at 50 mg (or matching placebo) with doses individualized based upon each patient's platelet response, ranging from once-daily doses of 25 mg to 75 mg, or less frequently. The baseline median platelet count in both the placebo and the PROMACTA groups was 16,000/microliters.

Throughout the study, the median platelet count in the placebo group never exceeded 30,000/microliters. By contrast, after just one week, patients in the PROMACTA arm experienced a rise in their median plate
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
2. GEN Reports on the Trend Toward Predictive Toxicogenomics
3. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
4. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
5. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
6. Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE(R)
7. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
8. Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
10. Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio
11. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , 31 juli 2014 De Pfizer Clinical ... rekruteringscampagne voor gezonde vrijwilligers van Japanse komaf voor medewerking ... gevestigde PCRU is één van twee onderzoekseenheden ... ideaal levens te verbeteren door de ontdekking en ontwikkeling ... PCRU op zoek naar mannen en vrouwen van Japanse ...
(Date:7/30/2014)... Mich. , July 30, 2014 Advanced Photonix ... quarter (ending June 27, 2014) financial results on Monday, August ... be released after the close of the market and the ... the results at 4:30 p.m. EDT on the same day. ... Kurtz (CEO and Director), Rob Risser (COO ...
(Date:7/30/2014)... July 30, 2014  Cepheid (Nasdaq: ... contract with Premier will end on September 30, ... will be able to continue their relationship with ... MedAssets, Novation, and ROi, in addition to the ... Cepheid. "Cepheid has always recognized and ...
Breaking Medicine Technology:Gezonde vrijwilligers van Japanse komaf gezocht voor deelname aan Fase I klinisch onderzoek 2Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3
... Advanced Sterilization Products (ASP) announced today the ... GLOSAIR™ Healthcare Environmental Decontamination – that provides effective, ... operating suites to reduce the risk of patient ... scientific consensus that the patient environment is a ...
... 2011 Reportlinker.com announces that a new ... catalogue: Product Profiles: Depression ... http://www.reportlinker.com/p0564398/Product-Profiles-Depression---Next-generation-vies-for-second-line-patients.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... Patents for the current market-leading depression brands ...
Cached Medicine Technology:ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities 2ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities 3ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities 4ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities 5Reportlinker Adds Product Profiles: Depression - Next generation Vies for Second-Line Patients 2Reportlinker Adds Product Profiles: Depression - Next generation Vies for Second-Line Patients 3Reportlinker Adds Product Profiles: Depression - Next generation Vies for Second-Line Patients 4Reportlinker Adds Product Profiles: Depression - Next generation Vies for Second-Line Patients 5
(Date:7/31/2014)... India (PRWEB) July 31, 2014 RankingBySEO, ... service for those individuals and organizations against whom negative ... as ‘Remove Negative Comments Service’. , About the ... “We have officially announced the service now, but we ... rid of negative comments for several years.” , On ...
(Date:7/31/2014)... 31, 2014 T.E.N., a technology ... honored finalists and winners Wednesday evening, July 30, ... Awards Gala at the Westin St. Francis in ... information security for the BlackLine Systems, was selected ... Award winner for the ISE® West Region. As ...
(Date:7/31/2014)... Steven Reinberg HealthDay Reporter ... regulation of electronic cigarettes isn,t warranted based on current ... contrary, allowing e-cigarettes to compete with regular cigarettes might ... reviewing 81 prior studies on the use and safety ... suggests that there is a potential for smokers to ...
(Date:7/31/2014)... India (PRWEB) July 31, 2014 ... Marketing Company, has introduced a new service named ... , Ethane Web Technologies has designed the service ... of clients and Java Development service being provided ... the company a confidence to promise outstanding Java ...
(Date:7/31/2014)... 2014 Bedros Keuilian’s Fit Body Boot Camp ... other countries. At his annual Fitness Business Summits, some of ... their marketing strategies. But in his latest blog post, he ... marketing a personal training business is to create free ... personal trainer has a certain area that they really feel ...
Breaking Medicine News(10 mins):Health News:RankingBySEO Launches a New Service ‘Remove Negative Comments’ 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 3Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2Health News:Bedros Keuilian’s New Post Explains the Value of Fitness Information Products in Marketing a Personal Training Business 2Health News:Bedros Keuilian’s New Post Explains the Value of Fitness Information Products in Marketing a Personal Training Business 3
... difference in effectiveness of 5 drugs currently available , , ... that any one of the five drugs available in ... the others, says an American College of Physicians (ACP) ... just issued a new guideline on drug treatment of ...
... Publishing, an award-winning interactive, visual content developer, today ... the first free, Web-based 3-D interactive model of ... educators, and health and medical professionals, The Visible ... how the human body works. It will also ...
... ANNAPOLIS, Md., March 4 Dozens of ... gathered in Annapolis today as,the General Assembly ... regulations, protections against identity theft, and the ... visited legislators,offices and attended committee hearings on ...
... Market Segments, CHICAGO, March 4 Throw ... Financial services firms, insurers, and,healthcare payors admit they ... to serve baby boomers, who will control some ... who make up the wealthiest generation in history, ...
... CA A nuclear receptor protein, known for controlling ... powerful anti-inflammatory effects in arteries, suppressing atherosclerosis in mice ... research by scientists at the Salk Institute for Biological ... , Their findings, reported in this weeks online edition ...
... swayed by adolescent drug use trends , , TUESDAY, March 4 ... boys are more likely to give up the habit if ... no matter what, new research shows. , The findings ... to the wider world,s embrace of illegal drugs, said study ...
Cached Medicine News:Health News:Groups Issue New Dementia Drug Guidelines 2Health News:Argosy publishing launches The Visible Body 2Health News:Argosy publishing launches The Visible Body 3Health News:Utilities, Long Term Care Bills at Center of 'AARP Day In Annapolis' 2Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 2Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 3Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 4Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 5Health News:New potential drug target for the treatment of atherosclerosis 2Health News:New potential drug target for the treatment of atherosclerosis 3Health News:Troubled Boys Will Abandon Pot When It's Deemed Uncool 2
... Sickle-Chex is a positive and negative ... presence of Hemoglobin S in solubility tests ... Streck SICKLEDEX and other manufacturers' solubility ... plastic squeeze dropper vial. The vial dispenses ...
... whole blood hematology control manufactured specifically for ... and the Coulter AcT5diff instruments. The composition ... cell differential, positioning the populations within the ... The product offers 105-day closed-vial stability and ...
... STaK-Chex, a whole blood assayed hematology ... five-part white cell differential available with the ... unique product has 14-day open-vial stability, 105-day ... normal and high levels. The 4.0ml pierceable ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Medicine Products: